Teva made over $200 million in profits resulting from payments to government officials in Ukraine, Russia and Mexico; now it will have to pay $519M in civil and criminal penalties. J&J held the previous record for the pharma sector in FCPA penalties of $70m.
Over $200 million in ill-gotten profits in a decade long crime spree has cost Teva Pharmaceutical Industries Ltd. a more than half a billion-dollar settlement with the Securities and Exchange Commission and the Department of Justice – a sum that appears to be the largest ever for a pharmaceutical company in violating the Foreign Corrupt Practices Act (FCPA).
An SEC investigation found that the generic drugs giant had bribed government officials in the Ukraine, Russia and Mexico to...
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
